Quick Answer
Contineum Therapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2024.
Contineum Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2024 | $0.00 | -100.0% |
| 2023 | $50.00M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | — | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| September 30, 2023 | $0.00 | — | -100.0% |
| June 30, 2023 | $50.00M | — | — |
- Contineum Therapeutics, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2023–2024 period, Contineum Therapeutics, Inc.’s revenue (asc 606) has declined by 100.0% (from $50.00 million to $0.00).
- The most recent figure is from Contineum Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 6, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: